0
Pulmonary Procedures |

Intracavitary Pulmonary Aspergilloma Removal Using Combined Virtual, Ultrathin, and Rigid Bronchoscopy - A Case Series

David Stather, MD; Alain Tremblay, MD; Paul MacEachern, MD; Alex Chee, MD; Jacob Gelberg, MD; Elaine Dumoulin, MD; Gary Gelfand, MD; Michael Parkins, MD; Christopher Mody, MD
Author and Funding Information

University of Calgary, Calgary, AB, Canada


Chest. 2013;144(4_MeetingAbstracts):817A. doi:10.1378/chest.1666716
Text Size: A A A
Published online

Abstract

SESSION TITLE: EBUS: New Approaches

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Tuesday, October 29, 2013 at 04:30 PM - 05:30 PM

PURPOSE: Intracavitary pulmonary aspergilloma is a chronic debilitating fungal infection associated with significant mortality. Without definitive therapy, death from aspergilloma can occur from massive hemoptysis, cachexia or secondary infection. While surgical resection has been the accepted treatment of choice, it is associated with significant morbidity and mortality and is not a therapeutic option for many patients because of poor pulmonary function or debility. Bronchoscopic removal in combination with antifungal therapy provides an important alternative therapy for this life threatening disease.

METHODS: We describe a series of 5 cases of bronchoscopic removal of intracavitary aspergilloma with a technique involving virtual bronchoscopy to guide the procedure, ultrathin bronchoscopy, rigid bronchoscopy, combined with antifungal therapy.

RESULTS: Successful removal of the aspergilloma with symptom improvement or resolution was achieved in all five cases. Minor post procedure hypoxia was observed in 3 cases. Severe sepsis requiring an extended critical care unit stay was seen in one case. Follow up ranged from 12 to 46 months.

CONCLUSIONS: This is the first reported case series of bronchoscopic removal of intracavitary pulmonary aspergilloma.

CLINICAL IMPLICATIONS: Although not without associated complications of minor hypoxia and possible sepsis, in carefully selected patients this new treatment modality provides an important alternative therapy for this life threatening disease.

DISCLOSURE: The following authors have nothing to disclose: David Stather, Alain Tremblay, Paul MacEachern, Alex Chee, Jacob Gelberg, Elaine Dumoulin, Gary Gelfand, Michael Parkins, Christopher Mody

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Emergency surgery for massive haemoptysis. Acta Chir Belg ;105(6):639-43.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543